Connexins are subunits of gap junction channels, which allow direct transfer of ions, secondary messenger molecules, and other metabolites between contacting cells. Gap junctions are believed to be involved in tissue homeostasis, embryonic development, and control of cell proliferation. Several studies have shown that cell damage signals are transmitted through gap junctions when cells are irradiated or when cells bearing the herpes simplex virus-thymidine kinase (HSV-TK) gene are treated with ganciclovir. We established 2 lines of transgenic rats with a dominant-negative mutant of connexin 32 gene under control of the albumin promoter. In the livers of transgenic rats, membrane localization of normal endogenous connexin 32 protein is disturbed, and gap junction capacity measured by scrape dye-transfer assay in vivo is markedly decreased when compared with wild-type rats. The present investigation concerned susceptibility to the liver-toxic substances D-galactosamine and carbon tetrachloride. These toxicants induced massive liver cell death and elevated serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels in the wild-type rats; however, much fewer liver cells were damaged and serum enzyme elevation was much lower in the transgenic rats. In conclusion, gap junctional intercellular communication (GJIC) plays an important role in toxic effects of chemicals; damage or death signals may pass through gap junctions in the rat liver in vivo.

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.20256DOI Listing

Publication Analysis

Top Keywords

transgenic rats
16
gap junctions
12
dominant-negative mutant
8
gap junction
8
wild-type rats
8
rats
6
gap
6
connexin dominant-negative
4
transgenic
4
mutant transgenic
4

Similar Publications

Introduction: Neuroinflammation derived from the activation of the microglia is considered a vital pathogenic factor of Alzheimer's Disease (AD). T-006, a tetramethylpyrazine derivative, has been found to alleviate cognitive deficits via inhibiting tau expression and phosphorylation in AD transgenic mouse models. Recently, T-006 has been proven to dramatically decrease the levels of total Amyloid β (Aβ) peptide and Glial Fibrillary Acidic Protein (GFAP) and suppress the expression of ionized calcium binding adaptor molecule-1 (Iba-1) in APP/PS1 mice.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.

Background: Imaging biomarkers have helped to reconceptualize Alzheimer's disease pathophysiology. More specifically, positron emission tomography (PET) radiopharmaceuticals for non-invasively assessing amyloid-beta (Aβ) plaques, glucose metabolism, and glial reactivity allow for tracking disease progression in a temporally ordered manner. However, whether transgenic models recapitulate biomarker-related changes remains elusive.

View Article and Find Full Text PDF

Developing Topics.

Alzheimers Dement

December 2024

Eisai Co., Ltd., Tsukuba, Ibaraki, Japan.

Background: Synaptic degeneration is characteristic of neurodegenerative diseases. Amyloid-beta (Aβ) plaques and neurofibrillary tangles of hyperphosphorylated tau are known to induce the synapse pathologies directly or indirectly in Alzheimer's disease (AD). EphA4 is a member of the ephrin receptor subfamily which is predominantly expressed in the brain.

View Article and Find Full Text PDF

Developing Topics.

Alzheimers Dement

December 2024

Aquinnah Pharmaceuticals, Cambridge, MA, USA.

Background: Increasing data indicates that the pathophysiology of microtubule associated protein tau is mediated by its interactions with RNA and RNA binding proteins via stress granules (SGs) and the translational stress response. Aquinnah now reports identifying small molecule compounds that inhibit tau/TIA1 SGs in neuronal cell lines and show strong in vivo efficacy in a classic mouse model of tauopathy.

Method: Compounds identified using high content imaging screening in SH-SY5Y neuroblastoma cells, inducibly over-expressing tau::GFP and TIA1::mKate2, following exposure to stressor.

View Article and Find Full Text PDF

Background: Imaging biomarkers have helped to reconceptualize Alzheimer's disease pathophysiology. More specifically, positron emission tomography (PET) radiopharmaceuticals for non-invasively assessing amyloid-beta (Aß) plaques, glucose metabolism, and glial reactivity allow for tracking disease progression in a temporally ordered manner. However, whether transgenic models recapitulate biomarker-related changes remains elusive.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!